Halozyme Therapeutics, Inc.
HALO
Halozyme Therapeutics, Inc. operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable biologics, such as monoclonal antibodies and other tā¦ read more
Healthcare
Biotechnology
21 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$64.66
Price-2.83%
-$1.88
1Y
Price
Market Cap
$7.604b
Mid
Price/Earnings 3y Avg5y Avg
13.6x
Premium
Premium
Financials Overview
Key metrics over the past few years+80.3%
EBITDA Margin+49.5%
Net Profit Margin+49.6%
Free Cash Flow MarginRevenue
$1.243b
+22.4%
1y CAGR+23.5%
3y CAGR+29.9%
5y CAGREarnings
$595.492m
+34.1%
1y CAGR+43.7%
3y CAGR+20.3%
5y CAGREPS
$4.75
+38.5%
1y CAGR+49.2%
3y CAGR+25.1%
5y CAGRBook Value
$503.915m
$2.221b
Assets$1.717b
Liabilities$1.511b
DebtDebt to Assets
68.0%
1.7x
Debt to EBITDAFree Cash Flow
$602.401m
+28.6%
1y CAGR+37.6%
3y CAGR+22.9%
5y CAGRFinancial Reports
Earnings and other important metrics. Amounts in USD.No items found.
Press Releases
Statements and updates from the company